Vistagen Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 25 →InsidersNo open-market buys or sales.→HoldersCommodore Capital 6.3%Vanguard 3.5%Two Sigma Investments 1.9%→Financing →PeersClosest companies: PRLD, ELVN, KYMR→
From the filings
Figures
- Revenue
- $2.5Mlast 12 months
- Net income
- −$67.6Mlast 12 months
- Operating cash flow
- −$62.3Mlast 12 months
- Cash and equivalents
- $17.0Mat the last balance sheet
- Shares outstanding
- 44.4M shareson issue